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Abstract
Purpose In quality-of-life (QL) research, the genetic
susceptibility of negative and positive emotions is fre-
quently ignored, taken for granted, or treated as noise. The
objectives are to describe: (1) the major findings of studies
addressing the heritable and environmental causes of var-
iation in negative and positive emotional states and (2) the
major biological pathways of and genetic variants involved
in these emotional states.
Methods Literature overview.
Results The heritability estimates for anxiety and
depression are 30–40%. Related traits as neuroticism and
loneliness are also highly heritable. The hypothalamo–
pituitary–adrenal axis is the ‘final common pathway’ for
most depressive symptoms. The many findings of investi-
gated genes are promising but not definitive. Heritability
estimates of positive emotional states range between 40
and 50%. Life satisfaction and mental health share com-
mon genetic factors with optimism and self-esteem. The
prefrontal cortex is a candidate brain area for positive
emotional states. Biological and genetic research into
positive emotional states is scarce.
Conclusion Genetically informative studies may provide
insights into a wide variety of complex questions that tra-
ditional QL studies cannot deliver. This insight in turn will
help us to design more effective supportive programs that
could moderate the outcomes of genetically based
predispositions.
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Abbreviations
SCN Suprachiasmatic nucleus
PVN Hypothalamic paraventricular nucleus
AVP Vasopressin neurons
CRH Corticotropin-releasing hormone
ACTH Adrenocorticotropin
Introduction
Psychological or mental functioning is one of the key
components of quality of life (QL) and encompasses the
entire spectrum of psychological well-being: from anxiety
and depression on the one hand to happiness and life sat-
isfaction on the other. Since being confronted with a dis-
ease is one of the major stressors in life, it is
understandable that patient-based QL research has focused
primarily on the negative end of this range. Frequently
used QL questionnaires, such as the European Organisation
for Research and Treatment of Cancer QL questionnaire
(EORTC QLQ-C30), exclusively inquire about negative
emotions (e.g., being tense, worried, irritable, depressed)
[1]. In the area of health psychology, the stress process has
also been described predominantly in terms of negative
emotions. This focus may have stemmed from the
acknowledgment that negative emotions have adaptive
value as they mobilize the fight/flight response and focus
attention on the problem at hand [2].
However, there is mounting evidence that positive
emotions co-occur with negative emotions during intensely
stressful periods of life [2, 3]. Positive emotions have also
been found to have adaptive significance as they may
broaden the individual’s attentional focus and behavioral
repertoire, thereby increasing the person’s intellectual,
social, and physical resources [4]. There is a growing
empirical body of research showing that positive emotions
have a salutary impact on health, particularly regarding the
immune system response and pain tolerance [5, 6]. In other
words, happy people are in general healthier. The World
Health Organization has started to emphasize happiness as
a component of health [7], and the British Medical Journal
has recently published an article on the dynamic spread of
happiness along connections in a large social network and
the implications for healthcare [8].
The balance between negative and positive emotions
may differ within persons over time, e.g. immediately after
the diagnosis of a disease, negative emotions will likely
prevail. The balance between negative and positive emo-
tions also differs across individuals. We all know persons
whose view on life is gloomy and somber irrespective of
happy and fortunate circumstances. Conversely, we can all
name people who persist in a sunny and cheerful view on
life despite setbacks and mayhem. In patient-based QL
research, this inborn nature is frequently ignored, taken for
granted, or treated as noise. The field of QL research would
benefit from taking this genetic component into account.
Insight into the genetic and environmental components of
patient-reported emotional states will ultimately allow us to
explore new pathways for improving patient care. If we can
identify patients who have a high risk of experiencing poor
psychological functioning, we will be able to better target
psychological support and/or pharmacological treatment.
In other words, we will be able to direct our limited
resources in a timely fashion to those who are most likely
to need them.
Research on twins, multi-generational families, and
population-based cohorts has provided ample empirical
evidence of a genetic predisposition for negative emotional
states, such as depression, anxiety, and loneliness. Addi-
tionally, an increasing number of studies showed sub-
stantial heritability of positive emotional states, such as
subjective well-being, happiness, and life satisfaction. The
objectives of this paper are first to describe the major
findings of the studies addressing the heritable and envi-
ronmental causes of variation in individual differences in
negative and positive emotional states. Second, we will
describe the major biological pathways of and genetic
variants involved in these emotional states. We will thus
describe those biological pathways and genetic variants
that affect QL, which is consistent with the adapted theo-
retical model of Wilson and Cleary [9] as described by
Sprangers et al. [10]. Since more biological and genetic
research has been conducted in negative than in positive
emotional states, the paper will reflect this imbalance.
Negative and positive emotional states are commonly
reported in separate papers. We purposefully bring these
findings together as helping patients to achieve a high level
of well-being requires targeting both negative and positive
affect.
Negative emotional states
Causes of individual differences
Genetic as well as environmental factors play a role in the
etiology of negative emotional states, such as anxiety and
depression. The heritability estimates for both anxiety and
depression disorders range between 30 and 40%. These
percentages most likely represent the lower bound. Actual
heritability may be higher when measurement error could
be ruled out and depression could be perfectly reliably
assessed [11, 12]. The remaining variance can be attrib-
uted to individual-specific environmental influences, as
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indicated by two meta-analyses [11, 12]. It should be noted
that the environmental influence already starts in the womb
[13]. According to twin and family studies, anxiety and
depression have a common genetic background. They also
share a common genetic factor with neuroticism. Thus, it is
likely that neuroticism is the personality trait underlying
these disorders [14, 15]. Neuroticism refers to the tendency
to experience negative emotions such as fear, sadness, and
anger. This trait is also being referred to as negative
affectivity or emotionality [16]. The heritability estimates
of neuroticism have also been found to range around
30–40% [17]. Findings in adolescents generally support
findings in adults and young children that neuroticism is
influenced principally by genetic and unique, non-shared
environmental factors [16].
Many patients may also experience the pain of loneli-
ness that a chronic or disabling disease may induce.
Loneliness can be described as feelings of social isolation
and dissatisfaction with one’s social relationships. There is
robust evidence that loneliness plays a pivotal role in
emotional states, such as mood, anxiety, anger, pessimism,
and dysphoria [18]. Loneliness also has a significant
genetic component. In a cross-sectional study of adult
twins, the heritability estimate for variation in loneliness
scores averaged over items and measurement occasions
was found to be around 50% [19]. In a longitudinal analysis
of two individual items (‘‘I feel lonely’’ and ‘‘Nobody loves
me’’), the heritability in young adults (below 35 years) was
found to be 77 and 70% respectively and 41 and 54% in
older adults [18]. This finding of a heritability of around
50% is replicated in children, using an average score of
loneliness over ages 7, 10, and 12 [20]. The longitudinal
analyses in this study show, however, that heritability is
58% at age 7, 56% at age 10 but drops to 26% at age 12. A
parallel increase in influences of shared family environ-
ment is observed, explaining 6% of the variance at age 7,
8% at age 10, and 35% at age 12. The remaining variance
is explained by relatively stable influences of non-shared
environmental factors. Stability in loneliness is high with
correlations over time ranging between 0.51 and 0.69,
indicating that individuals who score high on loneliness at
a young age have a substantial chance to stay lonely
throughout childhood, whereas gregarious youngsters have
a small chance of suddenly becoming lonely.
Biological pathways
In this section and the next section on genetic variants, we
will focus primarily on anxiety and depression, as these
negative emotional states elicited a great deal of biological
and genetic research. The hypothalamo–pituitary–adrenal
(HPA) axis is considered to be the ‘final common pathway’
for most depressive symptoms [13] and thus may be
important for patient-reported distress. Indeed, a large part
of the environmental and genetic risk factors for depression
appear to correlate with increased HPA-axis activity in
adults. Figure 1 illustrates the pathogenesis of depression
as formulated by Bao et al. [13]. In depressed patients,
stress acting on the HPA axis results in a disproportionately
high activity of this system due to a deficient cortisol
feedback effect. Such an impaired negative feedback
mechanism and overreaction of the HPA-axis to stress may
be based on genetic factors and environmental factors,
including placental dysfunction, smoking of the pregnant
mother, or child abuse. High corticotropin-releasing hor-
mone (CRH) and cortisol levels contribute to symptoms of
depression by their central effects. The set point of the
HPA-axis is at least partly genetically determined. For
example, the heritability estimate of basal cortisol levels
was found to be 62%, as indicated by a simultaneous
analysis of five comparable twin studies [21].
Fig. 1 Schematic illustration of the pathogenesis of depression
(reprinted with permission from Bao et al., 2008 [13], p. 541). The
schematic figure illustrates the impaired interaction among the
decreased activity of vasopressin neurons (AVP) in the suprachias-
matic nucleus (SCN), the increased activity of corticotropin-releasing
hormone (CRH) neurons in the paraventricular nucleus (PVN), the
increased release of adrenocorticotropin (ACTH) into the blood
stream by the pituitary gland, and the increased release of cortisol by
the adrenal gland. Normally, cortisol exerts a negative feedback effect
to shut down the stress response when the threat has passed. In
depressed patients, the cortisol feedback mechanism is deficient due
to the presence of glucocorticoid resistance, which may be caused
either by polymorphisms of the corticosteroid receptor or by early
(intra-uterine or childhood) developmental disorders. Both, increased
CRH and increased cortisol levels may induce mood disorders by
their central effects. The increased cortisol levels also affect the
vasopressin (AVP) neurons in the suprachiasmatic nucleus (SCN) as
they subsequently fail to inhibit sufficiently the CRH neurons in the
hypothalamic paraventricular nucleus (PVN). Such an impaired
negative feedback mechanism may lead to a further increase in the
activity of the HPA system [13]
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High cortisol levels in depression may result in an
impaired dopamine system [22], resulting in anhedonia
(insensitiveness to pleasure or incapacity for experiencing
happiness). Additionally, decreased levels of serotonin in
the brain are thought to be of importance in anxiety dis-
orders [23], panic disorders [24], and mood disorders,
although this latter relation is most probably reflecting a
vulnerability to suffer from depressive disorders [25].
Furthermore, sex hormone levels and particularly fluc-
tuations in sex hormone levels may play an important role
in the vulnerability to mood disorders [13]. Finally, the
suprachiasmatic nucleus, i.e. the biological clock, which
regulates circadian and circannual variations in neuronal,
hormonal, and behavioral activity, is also involved. It is
supposed to be related to circadian and circannual fluctu-
ations in mood and to sleeping disturbances in depression
and to hyperactivity of the HPA-axis [13].
Genetic variants
The genetic liability of a common familial disorder like
major depression involves multiple genes. Potentially
important genes have emerged that are related to the HPA
axis, e.g., those that affect AVP, CRH, or cortisol synthesis
as well as the production of their respective receptors.
Another frequently studied gene is catechol-o-methyl-
transferase (COMT) that is related to the monoamine
catabolism. Many other candidate genes have been pro-
posed and investigated.
To date, the genetic underpinning of depression has been
basically studied in three ways. First, linkage studies of
informative families have been conducted to identify
chromosomal regions (loci) likely to contain genes that
contribute to susceptibility of depression. For example,
several genome-wide linkage studies have identified
regions of chromosomes 15q [26–28], 17p, and 8p [27] to be
related to depression. Second, candidate gene association
studies have focused on functional polymorphisms (DNA
sequence variations that alter the expression and/or func-
tioning of the gene product) in previously identified and
new loci encoding for potentially relevant genes, as exem-
plified above. Many findings of this candidate gene
approach can be considered promising but not definitive.
The multiple genes involved in depression each exerts a
small effect, making genetic linkage and association studies
challenging [29]. Some consistent patterns have only
recently emerged. For example, the following five genes
were significantly associated with major depressive disor-
der in meta-analyses of polymorphisms that had been
investigated in at least three studies [30]: apolipoprotein E
(APOE), guanine nucleotide-binding protein (GNB3),
methylenetetrahydrofolate reductase (MTHFR), dopamine
transporter (SLC6A3), and serotonin transporter (SLC6A4).
Third, genome-wide association studies examine many
polymorphisms simultaneously in large samples of unre-
lated, population-based cases (those with depression) and
controls (those without depression). The first genome-wide
association study of depression examined more than
430,000 single nucleotide polymorphisms (SNPs) in 1,738
cases of major depression and 1,802 controls and suggested
preliminary evidence for the involvement of the pre-
synaptic protein piccolo (PCLO) on chromosome 7 [31].
The results from multiple replication cohorts (6,079 inde-
pendent cases with major depressive disorder and 5,893
controls) remained inconclusive. However, reanalysis of
the PCLO replication study indicated that there was con-
vincing evidence for the potentially causal association of
major depressive disorder with one particular SNP,
rs2522833, in PCLO [32]. Interestingly, the second gen-
ome-wide association study based on two large, indepen-
dent data sets and a further combined analysis using a
meta-analytical approach [33] failed to identify any SNP
that achieved significance. The authors concluded that
SNPs with substantial odds ratio are unlikely to exist for
major depression disorder, at least among the studied SNPs
to date.
A consistent, negative finding is worth mentioning.
According to the monoamine-deficiency hypothesis, defi-
cits in serotonin were thought to play a predominant role in
the pathophysiology of depression [34]. However, antide-
pressant drugs made to replenish the lack of these neuro-
transmitters, like serotonin reuptake inhibitors (SSRIs),
were shown not to be effective in large groups of patients
suffering from depression [22]. In addition, there is no
simple relationship between serotonin levels in the brain
and mood [25]. Moreover, the fact that SSRIs take weeks
to become effective makes also clear that the serotoniner-
gic system cannot play a primary role in mood disorders.
Finally, a recent meta-analysis was conducted of the
interaction between the serotonin transporter gene
(5-HTTLPR) and stressful life events on depression using a
total sample of 14,250 participants divided into cases and
controls. This study did not yield evidence that this serotonin
transporter gene alone or in interaction with stressful life
events is associated with an elevated risk of depression [35].
Positive emotional states
Causes of individual differences
An increasing number of twin studies showed substantial
heritability of positive emotional states, such as subjective
well-being and life satisfaction. Heritability estimates
ranged between 40 and 50%, whereas the remaining
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variance was accounted for by environmental influences
unique to an individual. No effects of environmental
influences shared by members of the same family were
found [36–44]. Bartels and Boomsma [45] examined the
etiology of different operationalizations of positive emo-
tional states: quality of life in general, satisfaction with life,
quality of life at present, and subjective happiness. Multi-
variate analyses with over 5,000 genetically related indi-
viduals revealed that the four measures all loaded on
similar sets of genes. Genetic factors specific to the four
measures were negligible.
A recent study by Boardman et al. [46] addressing the
heritability of resilience merits attention because of its op-
erationalization. Resilience was measured by a six-item
positive emotional measure (‘‘During the past 30 days, how
much of the time did you feel… cheerful? in good spirits?’’
etc.). They used the residual variance of this positive
emotional measure, after adjusting for an exhaustive list of
social and interpersonal stressors. In a sample of 527 twin
pairs, aged 25–74, the heritability of resilience for men was
found to be 52% and for women 38%. Thus, the residual
variance of positive affect or resilience was also found to be
heritable, albeit more for men than for women.
Personality characteristics such as optimism, self-
esteem, autonomy, mastery, personal growth, and self-
acceptance play important roles in mental health status
and subjective well-being [46–49]. For example, opti-
mism as defined in terms of positive generalized outcome
expectancies [50] may serve as a protective buffer against
mental as well as physical health impairments. Optimism
has been found to enhance, for example, adjustment to
heart disease [51] and cancer [52] (for a brief review of
such studies, see 49).
Recent twin studies indicate that these traits are not only
associated within individuals, but also tend to share com-
mon genetic factors with positive emotional states. For
example, multivariate genetic modeling of data derived
from 428 twin pairs, aged 23–24, indicated that genes
influencing optimism (measured with the Life Orientation
Test), self-esteem (measured with the Rosenberg scale),
and life satisfaction are largely overlapping [48]. The
largest study to date, using 3,053 twin individuals over
50 years, also found that the same set of genes was found
to be involved in optimism (also measured with the revised
Life Orientation Test), overall health (measured by a single
item: ‘‘how would you describe your health at present’’),
and mental health (measured with the General Health
Questionnaire, GHQ-12) [49]. Thus, these factors share a
genetic core that might represent the heritable mechanism
behind an individual’s positive orientation [48]. Never-
theless, a substantial amount of the variance in these traits
is still explained by non-shared, specific environmental
effects.
Biological pathways and genetic variants
Several studies suggest that the prefrontal cortex is a can-
didate brain area for happiness and positive emotional
states that may be related to taste [53], smell [54] or other
inputs via the somatosensory system [55]. Some electro-
encephalographic (EEG) studies suggest that positive
emotional states are associated with increased left cortical
power in the alpha frequency compared to the right
hemisphere [56, 57]. There is also evidence that dopamine
modulates positive emotional states [58], indicating a role
for the ventral tegmental area. At the subcortical level, a
number of neuropeptide systems have been implicated in
positive emotional states, e.g., neurotensin and cocaine-
and amphetamine-regulated transcript (CART) (both clo-
sely associated with dopamine), neuropeptide Y, and
oxytocin [58]. Finally, reduced activity of the neuroendo-
crine [59–61] and cardiovascular systems [58], as well as
increased activity of the immune system [58], may all be
involved in positive emotional states. However, genes or
genomic regions of interest for positive emotional states
have not been published at the time of paper writing.
Discussion
We have described the major results of the studies
addressing the heritability of and biological pathways and
genetic variants involved in negative and positive emo-
tional states, respectively. These affect states are to a
substantial degree heritable, with positive states being
slightly more heritable (40–50%) than negative states
(30–40%). The remaining variances can be attributed to
environmental influences unique to the individual, in which
the intrauterine period may play an important role. Perhaps
contrary to some people’s expectation, emotional states are
not affected by environmental influences shared by family
members. Another finding is that these mood states share
common genetic factors with related personality traits, such
as neuroticism for negative emotional states and optimism
and self-esteem for positive emotional states. An abun-
dance of studies have focused on the delineation of the
biological pathways of negative affect, with the HPA axis
considered as the ‘final common pathway’ of depressive
symptoms. By contrast, biological and genetic research
into positive emotional states is scarce. Multiple genes are
involved in emotional states, each exerting a small effect.
While the rate of progress is dazzling, particularly for
negative affect, the biological complexities do not allow
definitive answers yet.
A note of caution is warranted. The studies reviewed
employed very different samples, study designs, measures,
and analyses thereby potentially limiting their comparability.
Qual Life Res (2010) 19:1429–1437 1433
123
Particularly, the highly divergent self-report measures across
studies merit attention as reviews and meta-analyses generally
ignore these different sources. The question arises whether
such collapsing of data is warranted. The cited study by Bar-
tels and Boomsma [45] examining the etiology of four dif-
ferent operationalizations of positive affect is enlightening.
They found that the four measures were explained by one
underlying genetic factor and genetic factors specific to the
four measures were negligible. The implication of this finding
is that distinct measures of subjective well-being are not dis-
tinct at the genetic level and represent biological overlapping
constructs. Thus, different studies that collect distinct mea-
sures of positive emotional states can be compared. Moreover,
pooling data across measures is acceptable, at least for these
four measures of positive emotional state. Whereas this find-
ing is heartening, further research is needed to examine the
extent to which different measures assessing similar emo-
tional states, or QL domains, also share a similar genetic
factor.
An intriguing and pressing question is the extent to
which negative and positive emotional states share the
same biological and genetic substrate. There is evidence of
some common biological mechanism. For example, the
dopamine system is involved in negative as well as positive
affect. However, the relatively recent finding that high
levels of distress can co-occur with high levels of well-
being plead for, at least partly, independent biological
mechanisms. Clearly, further studies are needed to disen-
tangle the biological and genetic substrates of negative and
positive affect, using data sets that include information on
both phenotypes.
To avoid a possible misunderstanding about the impli-
cations of heritability studies, we would like to call atten-
tion to the fact that a high level of heritability does not
mean that environmental influences are unimportant. Genes
only influence phenotypes within an environment [46]. For
example, experimental manipulations of loneliness were
found to have powerful effects on mood, shyness, anxiety,
and self-esteem [in 18]. Moreover, interventions based on
simple and popular concepts such as committing acts of
kindness, expressing gratitude or forgiveness, and
thoughtful self-reflection had the power to induce a sus-
tainable increase in levels of happiness [62].
At this point, QL researchers may wonder why we need
to know the genes if we can examine the presence and
severity of depression, extent, and level of happiness, as
well as the related personality characteristics by self-report?
Molecular genetic studies may provide insights into a wide
variety of complex questions that traditional QL studies
cannot deliver. For example, how can we identify patients
who are vulnerable to long-lasting distress following a
diagnosis? How can we predict which patients will suffer
from mood disturbances when taking a specific chemo-
therapeutic regimen? Why do some pharmacotherapeutic
treatments not work in all patients with the ‘same’ level of
distress? Which patients would benefit from simple inter-
ventions to sustainably increase happiness? Why are some
psychotherapies not effective in comparable patients with
the same ‘problem’? Why do supportive interventions,
which one would expect to benefit all patients, often help
only a few? Delineation of biological pathways through
which various genetic predispositions propel people toward
negative or away from positive emotions is needed. More-
over, insight into which patients will respond to which
interventions can only be provided by studies assessing the
patients’ relative risk for negative and likelihood of positive
emotions using family and molecular genetic approaches in
combination with assessments of the risk and protective
environmental factors. This insight in turn will help us to
design more effective supportive programs that could
moderate the outcomes of genetically based predispositions.
For example, if we can identify which patients are
genetically predisposed to experience intense negative or
extreme positive affect, preventive measures such as self-
help programs or cognitive behavioral therapy can be
implemented. Further, if the patient is entering into a phase
of life where unavoidable stressors are present, such as a
diagnosis of a chronic disease, supportive care interven-
tions targeted at negative and positive affect or pharma-
cotherapy can be used concurrently with other treatments
that can ultimately lead to better treatment outcomes,
including survival. The individual, genetic profile would
thus help indicating which treatment or support would be
most helpful for a particular patient.
In sum, the combination of the prognostic value of
genetic, environmental risk and protective factors ulti-
mately enables appropriate and effective support [63].
Clearly, molecular genetic testing is a long way from being
implemented in clinical settings, and to some, the previ-
ously sketched vision might seem science fiction. However,
to realize this vision, we believe that QL research should
embrace the study of the genetic and environmental influ-
ences of both negative and positive affects as the resulting
insight will ultimately help our patients to become not only
happier but also healthier.
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Appendix: glossary [cited from 64]
Chromosome: Structure that is composed mainly of
chromatin, which contains DNA and resides in the nucleus
of cells.
DNA (deoxyribonucleic acid): The-stranded molecule
that encodes genetic information.
Family study: Assessing the resemblance between
genetically related parents and offspring and between sib-
lings living together. Resemblance can be due to heredity
or to shared family environment.
Gene: The basic unit of inheritance. A sequence of
DNA bases that codes for a particular product.
Genome: All the DNA sequences of an organism.
Genotype: The genetic constitution of an individual.
Heritability: The proportion of the phenotypic differ-
ences that can be attributed to genetic differences in a
particular population.
Linkage: Close proximity of loci on a chromosome.
Linkage analysis: A technique that detects linkage
between DNA markers and traits used to map genes to
chromosomes.
Locus (plural, loci): The site of a specific gene on a
chromosome.
Mapping: Linkage of DNA markers to a chromosome
and to specific regions of chromosomes.
Nucleus: The part of the cell that contains
chromosomes.
Phenotype: An observed characteristic of an individual
that results from the combined effects of genotype and
environment.
Polymorphism: A locus with two or more alleles
(alternative forms of a gene at a locus). (Functional poly-
morphism: DNA sequence variations that alter the
expression and/or functioning of the gene product)
Single nucleotide polymorphism (SNP): Sequences in
the genome that differ by a single nucleotide between one
portion of the population and another.
Twin study: Comparing the resemblance of identical
and fraternal twins to estimate genetic and environmental
components of variance.
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